TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25405764

Group type: EXPERIMENTAL
Intervention: Normal iron status
Number of subjects: 2443

Group type: EXPERIMENTAL
Intervention: Parasite infection
Number of subjects: 2443

Group type: EXPERIMENTAL
Intervention: Stunted children
Number of subjects: 2443

Group type: EXPERIMENTAL
Intervention: Anemia, iron, zinc, iodine, and vitamin A deficiency
Number of subjects: 2443
Study: 21699760

Group type: EXPERIMENTAL
Intervention: Endoscopic technique
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mini‐invasive technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Classical technique
Number of subjects: 60
Study: 15704687

Group type: EXPERIMENTAL
Intervention: Qianlie Sanyu Capsule
Number of subjects: 72

Group type: COMPARATOR
Intervention: Longbishu
Number of subjects: 72
Study: 11898913

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal pregnancy
Number of subjects: 0
Study: 9533118

Group type: EXPERIMENTAL
Intervention: Terumo Capiox SX25 (2.5 m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terumo Capiox SX18 (1.8 m2)
Number of subjects: 0
Study: 8077472

Group type: EXPERIMENTAL
Intervention: Topical propylthiouracil (PTU), applied three times daily for 4 to 8 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 9
Study: 2916335

Group type: EXPERIMENTAL
Intervention: 40 micron micro‐aggregate filter
Number of subjects: 11

Group type: COMPARATOR
Intervention: 170‐micron giving set filter
Number of subjects: 11
Study: 1087743

Group type: EXPERIMENTAL
Intervention: Ketoprofen (KETO), 200 mg daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA), 3.6 g daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study: 12532056

Group type: EXPERIMENTAL
Intervention: Fluoride-releasing glass ionomer cement
Number of subjects: 21

Group type: COMPARATOR
Intervention: Composite resin (no fluoride)
Number of subjects: 21
Study: 30269644

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (A‐tDCS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham tDCS (S‐tDCS)
Number of subjects: 14
Study: 26652797

Group type: EXPERIMENTAL
Intervention: Three doses of quadrivalent HPV vaccine on days 1, 60, and 180 or later
Number of subjects: 17729

Group type: EXPERIMENTAL
Intervention: Two doses of quadrivalent HPV vaccine on days 1 and 180 or later
Number of subjects: 17729

Group type: EXPERIMENTAL
Intervention: Two doses of quadrivalent HPV vaccine on days 1 and 60 by default
Number of subjects: 17729

Group type: EXPERIMENTAL
Intervention: One dose of quadrivalent HPV vaccine by default
Number of subjects: 17729

Group type: COMPARATOR
Intervention: All groups tested for incident HPV infections
Number of subjects: 17729

Group type: COMPARATOR
Intervention: Testing of cervical samples from participants
Number of subjects: 17729
Study: 24613188

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg sildenafil citrate
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 22266602

Group type: EXPERIMENTAL
Intervention: GVO+NSBB
Number of subjects: 95

Group type: COMPARATOR
Intervention: GVO alone
Number of subjects: 95
Study: 20633189

Group type: EXPERIMENTAL
Intervention: Active eradication therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18532873

Group type: EXPERIMENTAL
Intervention: Male circumcision in HIV-positive men
Number of subjects: 2746

Group type: COMPARATOR
Intervention: Male circumcision in HIV-negative men
Number of subjects: 2746

Group type: EXPERIMENTAL
Intervention: Resumption of intercourse before wound healing
Number of subjects: 2746
Study: 15378284

Group type: EXPERIMENTAL
Intervention: Athletes with MRAs
Number of subjects: 39

Group type: COMPARATOR
Intervention: Athletes without MRAs
Number of subjects: 39
Study: 12442020

Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal conjugate vaccine (n = 250)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo (n = 250)
Number of subjects: 500
Study: 10373132

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1 mg twice daily for three nights and 500 microg twice daily for 11 nights
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 8570977

Group type: EXPERIMENTAL
Intervention: On-waterbed (On-WB)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Baseline (standard incubator mattress)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Off-waterbed (Off-WB)
Number of subjects: 22
Study: 2240627

Group type: EXPERIMENTAL
Intervention: Isoflurane with 60% N2O
Number of subjects: 270

Group type: COMPARATOR
Intervention: Isoflurane without N2O
Number of subjects: 270
Study: 365325

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 30971279

Group type: EXPERIMENTAL
Intervention: Optimisation strategies for recruitment including adjustments to recruitment processes, additional recruiting sites, and a projection equation for recruitment estimates.
Number of subjects: 0
Study: 28501541

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sacral Neuromodulation
Number of subjects: 0
Study: 25474566

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no IPC)
Number of subjects: 15
Study: 23549825

Group type: EXPERIMENTAL
Intervention: Fully deflated LMA insertion
Number of subjects: 172

Group type: COMPARATOR
Intervention: Partially inflated LMA insertion
Number of subjects: 172
Study: 21624883

Group type: EXPERIMENTAL
Intervention: HibMenCY vaccine
Number of subjects: 4180

Group type: COMPARATOR
Intervention: Hib conjugate vaccine (ActHIB) and PedvaxHIB
Number of subjects: 4180
Study: 19435396

Group type: EXPERIMENTAL
Intervention: Automated voice message intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacy‐led outreach intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electronic medical record reminder intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 16454149

Group type: EXPERIMENTAL
Intervention: Specific acupressure treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo acupressure treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study: 15001401

Group type: EXPERIMENTAL
Intervention: HCT
Number of subjects: 136

Group type: COMPARATOR
Intervention: ConvRad
Number of subjects: 136
Study: 11731064

Group type: EXPERIMENTAL
Intervention: 1.0mg morphine-HCl
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 0.1mg morphine-HCl
Number of subjects: 53

Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 53
Study: 9041945

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rHuGH) for 1 year
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control levels (not specified)
Number of subjects: 18
Study: 8185094

Group type: COMPARATOR
Intervention: Room air ventilation (baseline)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nasal cannula (at 10 L/min)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oxygen supply tubing (at 15 L/min)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Demand valve
Number of subjects: 13
Study: 3503941

Group type: EXPERIMENTAL
Intervention: Information booklet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no booklet)
Number of subjects: 0
Study: 29364772

Group type: EXPERIMENTAL
Intervention: iCanDecide interactive and tailored Web site
Number of subjects: 537

Group type: COMPARATOR
Intervention: iCanDecide static Web site (control)
Number of subjects: 537
Study: 27221217

Group type: EXPERIMENTAL
Intervention: Forced air warming (active warming)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care (passive warming with heated cotton blankets)
Number of subjects: 140
Study: 25135364

Group type: EXPERIMENTAL
Intervention: Viable and revascularized before follow-up echocardiogram
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Viable, but medically treated
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Non-viable patients
Number of subjects: 224
Study: 23834410

Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil (group PR) - 56 μg/kg/min of propofol and 0.06 μg/kg/min of remifentanil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sevoflurane (group S) - 1.3 MAC
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil (group PR)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sevoflurane (group S)
Number of subjects: 120
Study: 19840300

Group type: EXPERIMENTAL
Intervention: Probiotic mix (Bifidobacterium bifidum BGN4, B. lactis AD011, Lactobacillus acidophilus AD031)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 18492366

Group type: EXPERIMENTAL
Intervention: Short GnRH agonist protocol with buserelin nasal sprays from day 2 and recombinant FSH from day 5
Number of subjects: 240

Group type: COMPARATOR
Intervention: Long GnRH agonist protocol with buserelin from previous mid-luteal phase and recombinant FSH after down-regulation
Number of subjects: 240
Study: 16466179

Group type: EXPERIMENTAL
Intervention: Yishen Jianpi Huayu Decoction (YJHD)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Coated aldehyde oxystarch (control)
Number of subjects: 43
Study: 12642847

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 10434785

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8919897

Group type: EXPERIMENTAL
Intervention: Inhalation of nitric oxide (NO) at a concentration of 30 ppm
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no inhalation of NO)
Number of subjects: 20
Study: 1882901

Group type: EXPERIMENTAL
Intervention: Sucralfate suspension (1 g q.i.d. for a maximum of 3 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7051805

Group type: EXPERIMENTAL
Intervention: L‐PAM
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: CFP
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: CFP with radiation therapy
Number of subjects: 293

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Myelosuppression levels
Number of subjects: 293
Study: 29140831

Group type: EXPERIMENTAL
Intervention: HBOC-201 (13 g Hb/dL)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Packed red blood cells (pRBCs) (24 g Hb/dL)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: HBOC-201
Number of subjects: 236

Group type: COMPARATOR
Intervention: Packed red blood cells (pRBCs)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: PolyHeme (10 g Hb/dL)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: PolyHeme
Number of subjects: 236
Study: 29038962

Group type: EXPERIMENTAL
Intervention: Modified lag screws
Number of subjects: 318

Group type: COMPARATOR
Intervention: Traditional miniplates
Number of subjects: 318
Study: 27704143

Group type: EXPERIMENTAL
Intervention: Trofile assay
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Genotype arm
Number of subjects: 155
Study: 24432009

Group type: EXPERIMENTAL
Intervention: Working memory-reasoning group
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Adaptive working memory-reasoning group
Number of subjects: 209

Group type: COMPARATOR
Intervention: Active control game group
Number of subjects: 209

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 209
Study: 21878488

Group type: EXPERIMENTAL
Intervention: Right hemisphere damage (RHD)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Left hemisphere damage (LHD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study: 18632252

Group type: EXPERIMENTAL
Intervention: Initial questionnaire concerning screening for diabetes (experimental group)
Number of subjects: 964

Group type: COMPARATOR
Intervention: No initial questionnaire (control group)
Number of subjects: 964
Study: 17620655

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 microg/d)
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1202
Study: 15134988

Group type: EXPERIMENTAL
Intervention: Apomorphine 2 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Apomorphine 3 mg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 11915639

Group type: EXPERIMENTAL
Intervention: ORABASE Soothe.N.Seal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical analgesics or systemic pain medications
Number of subjects: 0
Study: 9517578

Group type: EXPERIMENTAL
Intervention: Salbutamol combined with flunisolide (1 mg every 10 min for 3 hours)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Salbutamol and placebo (n = 47)
Number of subjects: 94
Study: 7923304

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/d
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg/d
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lovastatin and Pravastatin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lovastatin, Simvastatin, Pravastatin, Fluvastatin
Number of subjects: 25
Study: 3354811

Group type: EXPERIMENTAL
Intervention: Oxygen insufflation during laryngoscopy with an Oxyscope laryngoscope blade
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional laryngoscopy without oxygen insufflation
Number of subjects: 20
Study: 1405349

Group type: EXPERIMENTAL
Intervention: Isolated ultrafiltration (UF) at a rate of 1 to 1.5 liter/hr
Number of subjects: 12

Group type: COMPARATOR
Intervention: UF combined with bicarbonate hemodialysis (UF + HD)
Number of subjects: 12
Study: 845787

Group type: EXPERIMENTAL
Intervention: Failure at a task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior failure in depressed male subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior failure in nondepressed male subjects
Number of subjects: 0
Study: 31462579

Group type: EXPERIMENTAL
Intervention: Any webpage (chemical names only, names with quantity ranges, names with visual risk indicators)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Any webpage
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Visual risk indicator
Number of subjects: 1441

Group type: COMPARATOR
Intervention: No webpage
Number of subjects: 1441
Study: 31465093

Group type: COMPARATOR
Intervention: Fulvestrant alone
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Fulvestrant plus daily vistusertib
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Fulvestrant plus intermittent vistusertib
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Fulvestrant plus everolimus
Number of subjects: 333
Study: 29113664

Group type: EXPERIMENTAL
Intervention: Risk stratification model (score 0-17) based on factors such as impaired performance status, pre-existing medical illness, elevated ALP, urea, hypoalbuminemia, and major hepatectomy.
Number of subjects: 2613

Group type: COMPARATOR
Intervention: Validation of risk stratification model using Chi-square goodness-of-fit test.
Number of subjects: 2613
Study: 25350224

Group type: EXPERIMENTAL
Intervention: Gemigliptin + Rosuvastatin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gemigliptin + Irbesartan
Number of subjects: 60
Study: 24267513

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) - single dose of 2 grams
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 238
Study: 21282444

Group type: EXPERIMENTAL
Intervention: Single oral doses of solithromycin (50 to 1,600 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seven oral daily doses of solithromycin (200 to 600 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single oral dose of solithromycin (400 mg) with food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All dose regimens of solithromycin
Number of subjects: 0
Study: 19815268

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate 20 mg per day (n=243)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Placebo (n=238)
Number of subjects: 481
Study: 17187417

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily for 3 months
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 14985603

Group type: EXPERIMENTAL
Intervention: Telephone counselling service by the American Cancer Society
Number of subjects: 0
Study: 11465334

Group type: EXPERIMENTAL
Intervention: Low-power holmium laser (25 W)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Full-power holmium laser (80 W)
Number of subjects: 80
Study: 9779681

Group type: EXPERIMENTAL
Intervention: Rebox stimulation applied daily for 3 days using a negatively charged probe electrode, at pulse duration of 100 microsec, amplitude of 160 microamp, and frequency of 3000 Hz.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo Rebox stimulation.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Active Rebox stimulation.
Number of subjects: 30
Study: 7827943

Group type: EXPERIMENTAL
Intervention: 10.5 g wheat fibre (Trifyba) daily for 12 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: 60 ml lactulose daily for 12 weeks
Number of subjects: 38
Study: 3335948

Group type: EXPERIMENTAL
Intervention: Intermittent regimen (60 mg/m2/day for 4 weeks, followed by 40 mg/m2/day on 3 days a week for 4 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Long-term tapering regimen (60 mg/m2/day for 4 weeks, followed by the same dose on alternate days for 4 weeks and tapering by 10 mg/m2 on alternate days every 4 weeks for 5 months)
Number of subjects: 46
Study: 29617889

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 3508

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3508
Study: 29218126

Group type: EXPERIMENTAL
Intervention: Mini-resectoscope
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional resectoscope
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 26077412

Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg/week) or Adalimumab (40 mg/2 week) subcutaneously for 1 year
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 89
Study: 23219284

Group type: EXPERIMENTAL
Intervention: Benazepril and hydrochlorothiazide
Number of subjects: 11582

Group type: EXPERIMENTAL
Intervention: Benazepril and amlodipine
Number of subjects: 11582
Study: 21605608

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg kg⁻¹ BM
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study: 19598210

Group type: EXPERIMENTAL
Intervention: Heavy alcohol consumption (>=50 g of alcohol daily)
Number of subjects: 10920

Group type: EXPERIMENTAL
Intervention: Regular heavy drinking (>=4 drinks daily on >=5 days per week)
Number of subjects: 10920

Group type: EXPERIMENTAL
Intervention: Drinking >=50 g of alcohol daily in the finasteride arm
Number of subjects: 10920
Study: 16452559

Group type: EXPERIMENTAL
Intervention: Risperidone (3 mg daily for 8 weeks)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 68
Study: 15367067

Group type: EXPERIMENTAL
Intervention: Supportive tie condition
Number of subjects: 82

Group type: COMPARATOR
Intervention: Acquaintance condition
Number of subjects: 82
Study: 10879554

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Carotid angioplasty-stent (CAS)
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Both CEA and CAS
Number of subjects: 2500
Study: 8652810

Group type: EXPERIMENTAL
Intervention: Intensive timing induction therapy (4-day cycle of five active chemotherapeutic agents, second cycle 10 days after first cycle)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Standard timing induction therapy (4-day cycle of five active chemotherapeutic agents, second cycle 14 days or later after first cycle)
Number of subjects: 589
Study: 1310656

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA)‐coated APR Total Hip Replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Press‐fit only control group
Number of subjects: 0
Study: 6202993

Group type: EXPERIMENTAL
Intervention: Speech therapy (twice a week for 24 weeks)
Number of subjects: 191

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 191
Study: 30487976

Group type: EXPERIMENTAL
Intervention: MOVEdiabetes intervention (personalized consultations by dietitians, pedometers, monthly WhatsApp messages)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Usual care (comparison group)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: MOVEdiabetes intervention
Number of subjects: 232
Study: 28534446

Group type: EXPERIMENTAL
Intervention: Experimental-Moderate (EXP-Mod) diet
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Experimental-High (EXP-High) diet with 1000 mg n-3 fatty acids per serving
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (CON) diet from the US Military's Standard Garrison Dining Facility Menu
Number of subjects: 3
Study: 26268058

Group type: EXPERIMENTAL
Intervention: Liraglutide (LIRA)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Insulin glargine (IGla)
Number of subjects: 49
Study: 23899653

Group type: EXPERIMENTAL
Intervention: Multispecies probiotic supplement
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 21036279

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Microdiskectomy
Number of subjects: 40
Study: 18771508

Group type: EXPERIMENTAL
Intervention: Vaginal delivery (VD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cesarean section delivery (CSD)
Number of subjects: 12
Study: 15947629

Group type: EXPERIMENTAL
Intervention: Holmium laser bladder neck incision (HoBNI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Holmium enucleation of the prostate (HoLEP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Comparison of HoBNI and HoLEP
Number of subjects: 40
Study: 12531939

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation
Number of subjects: 144

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 144